Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Apple in Talks to Launch Online TV Service, 25 channels anchored by ABC, CBS and Fox
http://t.co/hOhOlMM5Jf
@MrTopStep: You think oil is cheap now just wait!!! : Iran Nuclear Deal Could Open Oil Flood Gates
GS predicts $20 $DTO
Looking to Elon Musk to come up with a super electric body battery.
earnings: Today after the close look for the following companies to report:
ANW, HELI, PRSC, JMEI, DCO, NES, MCP, QUNR, BDE, NOAH, BOOM, CALL, EGY, FTEK, XONE, CUI, FXEN, OMER
Tomorrow before the open look for the following companies to report:
BURL, ARCO, RYI, ZBRA, DSW, FDS, RSPP, PLUG, IOC
lol Here's when you're going to die http://read.bi/1bcjQlE
lucky Quebecers. lol
$AMGN up $4+ New Detailed Data From Phase 3 Study Show Amgen's Repatha(TM) (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol AMGN
Data From PCSK9 Inhibitor Study Support Regulatory Filing in Japan THOUSAND OAKS, Calif., March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha(TM) (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol. Data from the study showed subcutaneous Repatha 140 mg every two weeks or 420 mg monthly, compared to placebo, in combination with different daily doses of atorvastatin, reduced low-density lipoprotein cholesterol (LDL-C) by 67 to 76 percent from baseline at week 12 and at the mean of weeks 10 and 12. The data were presented at the American College of Cardiology's 64(th) Annual Scientific Session (ACC.15). In the YUKAWA-2 study, the most common adverse events that occurred in greater than 2 percent of the Repatha group were nasopharyngitis (16.8 percent Repatha; 17.8 percent placebo), gastroenteritis (3.0 percent Repatha; 1.0 percent placebo) and pharyngitis (2.5 percent Repatha; 2.5 percent placebo). "The positive results from this study in Japan add to the consistent findings we have seen with Repatha across patient populations in our comprehensive clinical program," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Statins are an important therapy for patients with high cholesterol and adding Repatha may help lower their LDL cholesterol levels when statins are not sufficient. We look forward to working with regulatory authorities in Japan to bring this new investigational medication to patients." Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.(1) In Japan, LDL-C levels are not adequately controlled for many high-risk patients taking statins, nearly half of whom have not reached their LDL-C goal.(2,3) "Statins are a cornerstone of treatment for people with high cholesterol who are unable to lower their LDL cholesterol to appropriate levels despite efforts to improve diet and exercise," said Arihiro Kiyosue, Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Japan, and Tokyo-Eki Center-building Clinic, Tokyo, Japan, and investigator for the YUKAWA-2 study. "We are encouraged by the results from the Phase 3 YUKAWA-2 study, which show that adding evolocumab to stable statin therapy in high-risk patients further reduced LDL cholesterol." High cholesterol is the most common form of dyslipidemia, which is an abnormality of cholesterol and/or fats in the blood.(4,5) There are approximately 300 million cases of dyslipidemia in the U.S., Japan and Western Europe.(6)
$IBB iShares NASD Biotech edges above Friday's multi-year high of 349.30 -- session high 349.80
$TGT new all time high.
Endo says it is dropping its bid for Salix after Valeant ups deal. cnbc
Monday: Industrial Production, Empire State Mfg, Homebuilder Confidence http://t.co/VBeCxtNGu4
ES Futures down 4.5 points so far...it's Fed week stay sharp.
Earnings Preview for the week of March 16 - 20
Of the companies reporting earnings for the week of March 16 - 20 some of the bigger names include:
Monday:
Pre Market - RDNT, STRL, TSQ, UCP, PGNX, PFNX
After Hours - ANW, HELI, PRSC, JMEI, DCO, NES, MCP, QUNR, BDE, NOAH, BOOM, CALL, EGY, FTEK, XONE, CUI, FXEN, OMER
Tuesday:
Pre Market - BURL, ARCO, RYI, ZBRA, DSW, FDS, RSPP, PLUG, IOC
After Hours - ORCL, ADBE, RATE, FRSH, CDNA, MCUR
Wednesday:
Pre Market - FDX, GIS, ATU, EJ, EVLV, LEJU
After Hours - JBL, WSM, CTAS, SFS, GES, MLHR, CLC, SCVL, TLYS, SLW, GOMO, KTWO, QEPM, RENN, JUNO
Thursday:
Pre Market - TECD, MIK, LEN, DANG, CATO, MCS, VNCE, TNP, CRCM
After Hours - NKE, MFRM, ZQK, CTRP, NWY, INGN, RALY, EXA, VCYT, VTL, ZFGN
Friday:
Pre Market - DRI, TIF, CMCM, KBH
US | Michigan Consumer Sentiment Prel for MAR: 91.2 (Cons: 95.5, Prev: 95.4)
earnings: Today after the close look for the following companies to report:
IRG, HIL, JMBA, OMED, MED, TEAR, ANAC, FF, FXCM, GST, KTOS, LOCO, ATHX, EGY, KRO, INGN, FTD, RMAX, ARO, ULTA, ZUMZ, IRET, PPHM
Tomorrow before the open look for the following companies to report:
RGEN, SPPI, EBIX, PETX, TA, BKE, ANN, HIBB, CTRN
$MS nHOD financials going to be hot this year. imho
Lumber Liquidators $LL conf call starts at 10AM ET
$LL halt news
$INTC *DJ Intel Lowers First-Qtr Rev Outlook = $Appl stealing their lunch.
Hey Dan. Wait for the first Fed rate increase and then we'll see lol.
Mela Sciences up big premarket on reimbursement codes for MelaFind system http://seekingalpha.com/news/2360166-mela-sciences-up-big-premarket-on-reimbursement-codes-for-melafind-system?source=feed_f … #premarket $MELA
earnings: Today after the close look for the following companies to report:
RST, SGMS, PLOW, MYRG, XOMA, IPAR, SCLN, HMIN, TAHO, CHMI, CNAT, VTAE, OME, ZOES, PWRD, XNET, KKD, CMTL, MNR, MW, WG, SHAK, NEFF, MCP, BLCM
Tomorrow before the open look for the following companies to report:
CRME, JRN, PWE, GLP, HWCC, LCUT, PHMD, PGEM, TLP, PETX, SNSS, LGIH, QIWI, RICE, LEAF, CSTM, JASO, BONT, KIRK, PLCE, SMRT, DG, GCO, MTN, CMN, HOV, SKIS, CVGW
DOE: US Crude Oil Stocks +4.512M Bbl In Wk; Seen +4.8M Bbl
US crude prices reverse to lowest since Feb 26 $DTO http://news.forexlive.com/!/us-crude-prices-reverse-to-lowest-since-feb-26-20150311 …
Gold fell for an eighth day in the longest run of losses in six years as a stronger dollar cut demand. $DUST $IAG
ScottWapnerCNBC How about this: EXCLUSIVE: Robert Chapman takes long position in $LL. Speaks to me at 12p about why Tilson's got it wrong.
Oh that's so the Fed I know! Thought about it and didn't do it. LoL
Good luck to him.
US Jan JOLTS job openings 4998K vs 5050K expected http://news.forexlive.com/!/jolts-job-openings-jan-2015-20150310 …
Wholesale inventories up 0.3% in January, versus expectations for 0.3% decline » http://cnb.cx/1GBisG4
US Jan JOLTS job openings 4998K vs 5050K expected http://news.forexlive.com/!/jolts-job-openings-jan-2015-20150310 …
The number of small businesses with unfilled job openings is at its highest level in 9 years. http://www.bloomberg.com/news/articles/2015-03-10/the-number-of-small-businesses-with-unfilled-job-openings-is-at-its-highest-level-in-nearly-9-years …
Qualcomm announces $15B buyback, raises dividend 14% » http://cnb.cx/1wlJrle (VIA @davidfaber)
earnings: Today after the close look for the following companies to report:
UNFI, CASY, URBN, ATTO, QIHU, MR, IDT, BRSS, KFY, VNET, KANG, MM, XOXO, WPRT, LMNR, FISH
Tomorrow before the open look for the following companies to report:
BKS, JW.A, SCAI, SUP, NNBR, BPI, LMIA, LINC, TCPC, MVIS, RDUS
needs more buyers.
up 25% pre open...Gevo Sells Renewable Jet Fuel to NASA $GEVO
Schedule for Week of March 8, 2015 http://t.co/QuZKX6FahP
MW Consumer credit rises 4.2% in January, slowest pace in 14 months
Consumer credit grew at a seasonally adjusted annual rate of 4.2%, for a gain of $11.6 billion in January, the Federal Reserve said Friday. This is the slowest pace of growth since November 2013. In the month, nonrevolving debt like car and student loans grew at a 6.3% rate. Revolving debt declined at a 1.6% rate in January after an 8.4% gain in the prior month. This is the biggest decline in credit card loans since November 2013. -Greg Robb; 415-439-6400; AskNewswires@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires (END) Dow Jones Newswires 03-06-15 1500ET Copyright (c) 2015 Dow Jones & Company, Inc.
MW Dow down 228 pts., but stocks paring losses